MY WHY ROBERT VICTOR VAN CAMP, DVM FEBRUARY 9TH, 1933 APRIL 7TH, - - PowerPoint PPT Presentation

▶
my why
SMART_READER_LITE
LIVE PREVIEW

MY WHY ROBERT VICTOR VAN CAMP, DVM FEBRUARY 9TH, 1933 APRIL 7TH, - - PowerPoint PPT Presentation

Apr 07, 2023 522 likes •741 views

IDEALHEALTHUS . COM MY WHY ROBERT VICTOR VAN CAMP, DVM FEBRUARY 9TH, 1933 APRIL 7TH, 2015 My Father , Robert Victor Van Camp , 77 y . o . retired DVM , diagnosed with Alzheimer s Disease ( AD ), 2011 Family sought any / all available

slide-1
SLIDE 1

ROBERT VICTOR VAN CAMP, DVM FEBRUARY 9TH, 1933 APRIL 7TH, 2015

MY WHY

IDEALHEALTHUS.COM

My Father, Robert Victor Van Camp, 77 y.o. retired DVM, diagnosed with Alzheimer’s Disease (AD), 2011 Family sought any/all available treatments for AD Contacted Maritza Novas, MD Brought Dad to Miami, Florida for first treatment August, 2012. Had mini- liposuction, Followed initial Adistem protocol with collagenase, then SVF infused through peripheral IV Second treatment in Miami, Florida, May

  • 2012. At this time, I trained to perform the

procedure in Kansas

slide-2
SLIDE 2

ALZHEIMER'S TRIAL

IDEALHEALTHUS.COM

slide-3
SLIDE 3

July 2012, meet with the Kansas Board of Healing Arts, in Topeka, Kansas. Advised only way to perform this procedure was through approved research from the Institutional Review Board (IRB)

  • f the International Cell Surgical Society (ICSS)

Wrote AD research protocol - "Intravenously Administered Autologous, Adipose-Derived Stromal Vascular Fraction in the Treatment of Alzheimer’s" Protocol Approved on Sept 26, 2013 with Protocol Number: A3-AZ-3701

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

AD RESEARCH

slide-4
SLIDE 4

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

CERTIFICATE OF APPROVAL BY THE IRB

Recruited: 4 AD patients Each had minimal to moderate cognitive Impairment Began treatment: November, 2013

AD SVF RESEARCH

slide-5
SLIDE 5
  • 1. SLUMS (St. Louis Mental Status Exam)
  • 2. Neurologist Confirmiation of Diagnosis of AD
  • 3. MRI Brain Scan

Scale is 1 -3, with 30 being normal function Patients for trial must of had a 17 or above (minimal to early moderate cognitive imparement) No other underlying neurological findings (past CVA, Brain neoplasm, and hydrocephaly)

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

REQUIRED STUDIES PRIOR TO TREATMENT

slide-6
SLIDE 6
  • 6. Diagnostic LP
  • 5. SPECT Imaging of Brain

Findings consistent with AD Beta-Amyloid, Total Tau Protein markers

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

REQUIRED STUDIES PRIOR TO TREATMENT

  • 4. CT Brain Scan

No active hemorrhage or prior hemorrhage with associated encephalomalacia

slide-7
SLIDE 7

Miniliposuction completed with sonographic guidance Bone Marrow performed with fluoroscopic guidance Diagnostic LP performed with fluoroscopic guidance SONOGRAPHIC FLUOROSCOPIC

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

ITEMS UNIQUE TO OUR TRIAL

slide-8
SLIDE 8

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

SPECT BRAIN SCANNER

slide-9
SLIDE 9

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

PROTOCOL: ORDER OF TREATMENT & DIAGNOSTIC STUDIES

slide-10
SLIDE 10

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

OUR RESULTS

Individual Effects of the MSC Intervention within Alzheimer's Patients Table 1;

slide-11
SLIDE 11

TREATMENT

TREATMENT

BEFORE AFTER

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

AD BEFORE & AFTER TREATMENT

slide-12
SLIDE 12

Small "n" Used both Mesenchymal (miniliposuction) and Hematopoietic (bone marrow) SVF Studied B-Amyloid, and Total Tau in CSF (Next protocol use: Total Tau and Phosphorylated Tau, and A-B-Amyloid 41) Included minimally-cognitively impaired and early moderately cognitively impaired AD patients No outside funding: Patients Paid Cost + 10% to participate in this Phase 1-Investigator Driven Research

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

LIMITATIONS OF THE TRIAL

slide-13
SLIDE 13

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

THE JOURNAL OF AMERICAN PHYSICIANS & SURGEONS

Accepted for publication in the 2019 Spring Edition.

slide-14
SLIDE 14

COPD TRIAL

IDEALHEALTHUS.COM

slide-15
SLIDE 15

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

COPD TRIAL

IRB Protocol approved, August, 2014. 5 patients Confirmed diagnosis of emphysema based on Pulmonary Function Studies, Computed Tomography and Chest X-Ray changes, pulmonary s/s Screening: Pulm exam, PFT’s, PA/Lat CXR, CT Chest Treatment x 3 (one treatment every 3 months), Fluoroscopic Guided Bone Marrow Aspirate and SVF, Collection of Platelet Rich Plasma, 1.5 cc’s of SVF mixed with 1.5 cc’s of PRP nebulized/aerosolized over 20-30 minute interval, the remainder of PRP and SVF given intravenously

  • ver 3 hours.

PFT’s repeated 1 week after the second treatment, q 3 months repeat of Pulm exam, PFT’s, PA/Lat CXR, CT Chest

slide-16
SLIDE 16

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

MIDWEST RADIOLOGY PULMONARY FUNCTION TEST

slide-17
SLIDE 17

All 5 patients experienced improved PFT’s after 3 treatments. All 5 patients had clinical improvement. All 5 patients showed some improved aeration of lungs and decreased inflammation t/o lungs on CT scan of the chest.

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

COPD TRIAL RESULTS

slide-18
SLIDE 18

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

PT: CG, PFT’S: (09/2014)

slide-19
SLIDE 19

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

PT: CG, PFT’S (07/2015)

slide-20
SLIDE 20

IDEALHEALTHUS.COM IDEALHEALTHUS.COM

HR CT CHEST SCAN